# ADHD

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/adhd
Canonical HTML page: https://gethealthbrief.com/entity/adhd

## Recent coverage (1 stories)

### GLP-1s and ADHD: The Next Frontier of Metabolic Psychiatry and Market Expansion
2026-03-10 08:08:37 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Emerging research and anecdotal reports suggest that GLP-1 receptor agonists, such as Ozempic, may alleviate symptoms of ADHD by modulating dopamine pathways in the brain. This potential crossover application could redefine the treatment landscape for neurodivergent patients, particularly amidst ongoing global shortages of traditional stimulant medications.
Full story: https://gethealthbrief.com/story/glp-1-adhd-symptoms-market-trends

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.